Healthcare Services company Indegene announced Q3FY26 results Revenue: Rs 9,421 million against Rs 7,204 million during Q3FY25, change 31%. EBITDA: Rs 1,747 million against Rs 1511 million during Q3FY25, change 16%. EBITDA Margin: 18.5% for Q3FY26. PAT: Rs 1,026 million against Rs 1097 million during Q3FY25, change -6%. PAT Margin: 10.9% for Q3FY26. Manish Gupta, Chairman & CEO, Indegene, said: “We delivered a standout Q3FY26, with revenue growing over 30% YoY and 17% sequentially, marking it the first USD 100 million+ revenue quarter. Our revenue per employee has crossed the USD 70K annual mark - the highest in the industry - underscoring the tangible impact of technology and AI in scaling productivity.”, “This quarter, 3 customers surpassed the USD 25 million annual revenue milestone, and 52 customers exceeded the USD 1 million annual level, reinforcing the depth of our client relationships. We also secured several breakthrough wins, where clients are partnering with us to combine our proven execution strength with AI to transform their operations and unlock differentiated, measurable outcomes. This momentum positions Indegene well to continue delivering sustained, profitable growth over the long term.” Suhas Prabhu, CFO, Indegene, said: “During the quarter, we completed the acquisitions of BioPharm, a US-focused life sciences omnichannel business, and Warn & Co., a UK-based consulting firm - both strategically important additions that deepen our domain expertise and expand our high-value capabilities. Our cash and investments are a healthy Rs 13,954 million, net of acquisition outflows, with continued cash generation strengthening our balance sheet. EBITDA adjusted for one-time expenses, rose to Rs 1,747 million, growing 15.7% YoY and 19.6% sequentially.” “While reported PAT remained flat at Rs 1,026 million this quarter, due to one-time expenses and higher non-cash amortization, these impacts are transient. As integration synergies are realized, acquisition-related costs taper off, and growth momentum continues, we expect profitability to continue to strengthen, supporting further EPS expansion.” Result PDF